Management of androgenetic alopecia
- PMID: 10461639
Management of androgenetic alopecia
Abstract
Background: Androgenetic alopecia (AGA) is the most frequent cause of hair loss affecting up to 50% of men and 40% of women by the age of 50.
Methods: This paper outlines the current status of diagnosis and offers guidelines for optimal management of AGA in both men and women.
Results: The diagnosis of AGA can usually be confirmed by medical history and physical examination alone. A trichogram can be useful to assess the progression of the hair loss. A scalp biospy is diagnostic but usually not required. In women with signs of hyperandrogenism, investigation for ovarian (polycystic ovarian disease) or adrenal (late-onset congenital adrenal hyperplasia) disorders is required. Mild to moderate AGA in men can be treated with oral finasteride or topical minoxidil. Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years. The drug is effective for both frontal and vertex hair thinning. Medical treatment with finasteride or minoxidil should be continued indefinitely since interruption of therapy leads to hair loss with return to pretreatment status. Mild to moderate AGA in women can be treated with oral antiandrogens (cyproterone acetate, spironolactone) and/or topical minoxidil with good results in many cases. Hair systems and surgery may be considered for selected cases of severe AGA both in men and in women.
Conclusions: Patients with AGA should be informed about the pathogenesis of the condition. If used correctly, available medical treatments arrest progression of the disease and reverse miniaturization in most patients with mild to moderate AGA.
Similar articles
-
Hair loss in women.Semin Cutan Med Surg. 2009 Mar;28(1):19-32. doi: 10.1016/j.sder.2009.01.001. Semin Cutan Med Surg. 2009. PMID: 19341939 Review.
-
Current management of androgenetic alopecia in men.Eur J Dermatol. 1999 Dec;9(8):606-9. Eur J Dermatol. 1999. PMID: 10586125 Review.
-
Androgenetic alopecia and current methods of treatment.Acta Dermatovenerol Alp Pannonica Adriat. 2005 Mar;14(1):5-8. Acta Dermatovenerol Alp Pannonica Adriat. 2005. PMID: 15818439 Review.
-
An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.Dermatology. 2004;209(2):117-25. doi: 10.1159/000079595. Dermatology. 2004. PMID: 15316165 Clinical Trial.
-
Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness.Br J Dermatol. 2011 Dec;165 Suppl 3:12-8. doi: 10.1111/j.1365-2133.2011.10630.x. Br J Dermatol. 2011. PMID: 22171680 Review.
Cited by
-
Observation of the Expression of Vascular Endothelial Growth Factor and the Potential Effect of Promoting Hair Growth Treated with Chinese Herbal BeauTop.Evid Based Complement Alternat Med. 2021 Feb 17;2021:6667011. doi: 10.1155/2021/6667011. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 33680060 Free PMC article.
-
Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia.Postepy Dermatol Alergol. 2014 Aug;31(4):207-15. doi: 10.5114/pdia.2014.40925. Epub 2014 Sep 8. Postepy Dermatol Alergol. 2014. PMID: 25254005 Free PMC article.
-
Understanding patient and physician perceptions of male androgenetic alopecia treatments in Asia-Pacific and Latin America.J Dermatol. 2017 Aug;44(8):892-902. doi: 10.1111/1346-8138.13832. Epub 2017 Mar 31. J Dermatol. 2017. PMID: 28370105 Free PMC article.
-
Low-Level Light Therapy and Minoxidil Combination Treatment in Androgenetic Alopecia: A Review of the Literature.Skin Appendage Disord. 2023 Mar;9(2):104-110. doi: 10.1159/000527782. Epub 2022 Dec 23. Skin Appendage Disord. 2023. PMID: 36937156 Free PMC article.
-
[Androgenetic alopecia. Current aspects of a common phenotype].Hautarzt. 2003 Aug;54(8):703-12. doi: 10.1007/s00105-003-0561-y. Hautarzt. 2003. PMID: 12942184 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous